Novartis announced that Pluvicto has been approved by the FDA for PSMA-positive metastatic hormone-sensitive prostate cancer, which is expected to drive new standards for the treatment of metastatic prostate cancer.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.